Company Encyclopedia
View More
name
Vaxcyte
PCVX.US
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria. The company was formerly known as SutroVax, Inc.
1.946 T
PCVX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Vaccine Stocks Drop After FDA Memo Links COVID Shots To Child Deaths

    Vaccine stocks, including Moderna, BioNTech, Novavax, and Vaxcyte, dropped significantly after an FDA memo linked COVID-19 vaccines to child deaths. The memo suggests upcoming regulatory restrictions, particularly for the 12-24 age group, affecting vaccine makers' market performance. Analysts foresee further challenges for Moderna and other companies due to potential regulatory changes. The memo's tone may contribute to vaccine skepticism and declining vaccination rates.

    Talkmarkets·
    US
    NOV
    -0.12%
    US
    MRNA
    +1.23%
    US
    PCVX
    -3.42%
    Talkmarkets·
    US
    NOV
    -0.12%
    US
    MRNA
    +1.23%
    US
    PCVX
    -3.42%

    Mizuho Securities Sticks to Their Buy Rating for Vaxcyte (PCVX)

    Mizuho Securities analyst Salim Syed maintained a Buy rating for Vaxcyte, setting a price target of $163.00. Syed, who covers the Healthcare sector, has an average return of -4.1% and a 41.09% success rate. Vaxcyte holds a Strong Buy consensus among analysts, with a consensus price target of $90.33.

    Tip Ranks·
    US
    PCVX
    -3.42%
    Tip Ranks·
    US
    PCVX
    -3.42%

    TD Cowen Reiterates “Buy” Rating on Vaxcyte (PCVX) With $50 PT

    TD Cowen analyst Tara Bancroft has reiterated a "Buy" rating on Vaxcyte, Inc. (NASDAQ:PCVX) with a price target of $50. The company is noted for its significant upside potential and hedge fund interest, making it one of the 15 stocks expected to perform well in 2026. This announcement follows positive Phase II data for the company.

    MSN·
    US
    PCVX
    -3.42%
    MSN·
    US
    PCVX
    -3.42%

    BTIG Keeps Their Buy Rating on Vaxcyte (PCVX)

    BTIG analyst Thomas Shrader has maintained a Buy rating on Vaxcyte (PCVX) with a price target of $85.00. The overall analyst consensus for Vaxcyte is a Strong Buy, with an average price target of $90.33. Shrader, who focuses on the Healthcare sector, has an average return of 2.6% and a 38.40% success rate on his stock recommendations.

    Tip Ranks·
    US
    PCVX
    -3.42%
    Tip Ranks·
    US
    PCVX
    -3.42%

    Vaxcyte (NASDAQ:PCVX) Releases Quarterly Earnings Results, Misses Estimates By $0.29 EPS

    Vaxcyte (NASDAQ:PCVX) reported quarterly earnings of ($1.56) EPS, missing estimates by $0.29. The company had a one-year low of $27.66 and a high of $116.00, with a market cap of $5.37 billion. Analysts have mixed ratings, with one Strong Buy, five Buy, one Hold, and one Sell. Institutional investors own 96.78% of the stock. Vaxcyte focuses on developing novel protein vaccines for bacterial diseases, including its lead candidate VAX-24 for pneumococcal disease.

    Market Beat·
    US
    PCVX
    -3.42%
    Market Beat·
    US
    PCVX
    -3.42%
    © 2025 Longbridge｜Disclaimer